Meningococcocal vaccine programme approved

August 20, 2002

The Government has approved a national meningococcal disease vaccination programme that will provide free meningococcal vaccines for all Australian children aged 12 months and 15 years, the Federal Minister for Health and Ageing, Senator Kay Patterson, has announced.

Also included in the first year of the national programme will be free vaccines for adolescents aged 16 and 17 years to ensure the greatest number of children in high risk age groups for meningococcal disease get access to free vaccines.

The free vaccine programme will begin in early 2003.

The Federal Government has also made a long-term commitment to fund a national meningococcal vaccination programme for the next 14 years.

Senator Patterson said: "Today's decision to introduce a national meningococcal vaccination programme is a responsible and pro-active approach to meningococcal disease management in this country.

"This approach ensures free vaccine is made available to the key age groups affected by meningococcal disease and it will, in time, have a significant impact on the number of meningococcal disease cases in Australia and will save lives."

Senator Patterson said a worldwide shortage of meningococcal vaccine had meant an effective national vaccination campaign could not be started earlier than next year.

About 1.1 million doses of vaccine are required for the proposed national programme. Currently there is only one registered supplier of the new conjugate vaccine in Australia and a current supply of about 100,000 doses available to the end of this year. Two other vaccine manufacturers currently have meningococcal C-type vaccines being considered for registration by the Therapeutic Goods Administration for use in Australia.

"More doses of the meningococcal group C conjugate vaccine are expected in the country in the coming months and my Department is working closely with industry to monitor available supply. The shortages are a global problem," Senator Patterson said.

The majority of meningococcal cases seen in Australia are meningococcal type-B disease (62 per cent) for which there is presently no vaccine on the market. About 32 per cent of all meningococcal cases in Australia are the type-C bacteria for which the new vaccine programme will provide protection.

 


 

Sponsored links

myDr Newsletter

Get myDr delivered to your inbox
Advertisement
See your doctor for diagnosis MIMS Consumer Health Group logo UBM Medica logo Hitwise Top 10 website This website is certified by Health On the Net Foundation. Click to verify. HealthInsite Quality Health Information ABA audited website - click to view latest stats
This web site is intended for Australian residents and is not a sbstitute for independent professional advice. Information and interactions contained in ths Web site are for infomation purposes only and are not intended ot be used to diagnose,treat , cure or prevent any disease.Further , the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. UBM Medica Australia Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incured by use of or relance on the information made available via or throught myDr whether arising from negligence or otherwise.
See Privacy Policy and Disclaimer.